Document:

NOTICE
OF GRANT OF NON-QUALIFIED STOCK OPTION

 

FTE
NETWORKS, INC.

 

2017
OMNIBUS INCENTIVE PLAN

 

FOR
GOOD AND VALUABLE CONSIDERATION, FTE Networks, Inc. (the “Company”) hereby grants, pursuant to the provisions
of the FTE Networks, Inc. 2017 Omnibus Incentive Plan (the “Plan”), to the Grantee designated in this Notice
of Grant of Non-qualified Stock Option (the “Notice of Grant”), a Non-qualified Stock Option to purchase the
number of Shares set forth in the Notice of Grant (the “Option”), subject to certain terms and conditions as
outlined below in the Notice of Grant and the additional terms and conditions set forth in the attached Terms and Conditions of
Stock Option (together with the Notice of Grant, the “Award Agreement”).

 

	Grantee:	[Name]
	 	 
	Type
    of Option:	Non-qualified
    Stock Option
	 	 
	Grant
    Date:	[Date]
	 	 
	Number
    of Shares Purchasable:	[####]
	 	 
	Option
    Price per Share:	$[#.##],
    which is the Fair Market Value as of the Grant Date
	 	 
	Expiration
    Date:	[Date],
    which is 10 years from the Grant Date
	 	 
	Exercisability
    Schedule:	[Insert
    schedule – time-based or performance-based]
	 	 
	Acceleration
    of Vesting on Separation from Service:	[Add
    provisions if applicable; otherwise delete.]
	 	 
	Acceleration
    of Vesting on Change in Control:	[Add
    provisions if applicable; otherwise delete.]
	 	 
	Exercise
    after Separation from Service:	Separation
    from Service for any reason other than death, Disability or Cause: any non-exercisable portion of the Option expires immediately
    and any exercisable portion of the Option remains exercisable for [90 days] following Separation from Service for any reason
    other than death, Disability or Cause;

    

    Separation from Service due to death or Disability: any non-exercisable portion of the Option expires immediately and
    any exercisable portion of the Option remains exercisable for [12 months] following Separation from Service due to death or
    Disability; and

    

    Separation from Service for Cause: the entire Option, including any exercisable and non-exercisable portion, expires
    immediately upon Separation from Service for Cause.

    

    In no event may THE Option be exercised after the Expiration Date as provided above.

 

By
signing below, the Grantee agrees that the Option is granted under and governed by the terms and conditions of the Plan and the
Award Agreement, as of the Grant Date.

 

	GRANTEE	 	 	FTE NETWORKS, INC.
	 	 	 	 
	Sign
    Name:	 	 	Sign
    Name:	 
	 	 	 	 	 
	Print
    Name:	 	 	Print
    Name:	 
	 	 	 	Title:	 
	 	 	 	 	 

 

    	Notice of Grant - Page 1

    	 

    

 

TERMS
AND CONDITIONS OF STOCK OPTION

 

1.
Grant of Option. The Option granted to the Grantee and described in the Notice of Grant is subject to the terms and conditions
of the Plan. The terms and conditions of the Plan are hereby incorporated herein by reference in their entirety. Except as otherwise
expressly set forth herein, the Award Agreement shall be construed in accordance with the terms and conditions of the Plan. Any
capitalized term not otherwise defined in the Award Agreement shall have the definition set forth in the Plan.

 

The
Board has approved the Plan. The Committee has approved the grant to the Grantee of the Option, conditioned upon the Grantee’s
acceptance of the terms and conditions of the Award Agreement within 60 days after the Award Agreement is presented to the Grantee
for review.

 

The
Option shall be treated as a Non-qualified Stock Option.

 

2.
Exercise of Option.

 

(a)
Right to Exercise. The Option shall be exercisable, in whole or in part, during its term in accordance with the Exercisability
Schedule set forth in the Notice of Grant and with the applicable provisions of the Plan and the Award Agreement. No Shares shall
be issued pursuant to the exercise of the Option unless the issuance and exercise comply with applicable laws. Assuming such compliance,
for income tax purposes the Shares shall be considered transferred to the Grantee on the date on which the Option is exercised
with respect to such Shares. Until such time as the Option has been duly exercised and Shares have been delivered, the Grantee
shall not be entitled to exercise any voting rights with respect to such Shares, shall not be entitled to receive dividends or
other distributions with respect thereto and shall not have any other rights of a Stockholder with respect thereto.

 

(b)
Method of Exercise. The Grantee may exercise the Option by delivering an exercise notice in a form approved by the Company
(the “Exercise Notice”), which shall state the election to exercise the Option, the number of Shares with respect
to which the Option is being exercised, and such other representations and agreements as may be required by the Company. The Exercise
Notice shall be accompanied by payment of the aggregate Option Price as to all Shares exercised. The Option shall be deemed to
be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Option Price (as
well as any applicable withholding or other taxes).

 

(c)
No Acceleration of Exercisability. The exercisability of the Option shall not be accelerated under any circumstances, except
as otherwise provided in the Plan.

 

3.
Method of Payment. If the Grantee elects to exercise the Option by submitting an Exercise Notice in accordance with Section
2(b) above, the aggregate Option Price (as well as any applicable withholding or other taxes) shall be paid by cash or check;
provided, however, that the Committee may consent to payment in any of the following forms, or a combination of them:

 

(a)
cash or check;

 

(b)
a “net exercise” under which the Company reduces the number of Shares issued upon exercise by the largest whole number
of Shares with a Fair Market Value that does not exceed the aggregate Option Price and any applicable withholding, or such other
consideration received by the Company under a cashless exercise program approved by the Company in connection with the Plan;

 

(c)
surrender of other Shares owned by the Grantee that have a Fair Market Value on the date of surrender equal to the aggregate Option
Price of the exercised Shares and any applicable withholding; or

 

(d)
any other consideration that the Committee deems appropriate and in compliance with applicable law.

 

    	Terms and Conditions - Page 1

    	 

    

 

4.
Restrictions on Exercise. The Option may not be exercised if the issuance of the Shares upon exercise or the method of
payment of consideration for those Shares would constitute a violation of any applicable law, regulation or Company policy.

 

5.
Non-Transferability of Option. The Option may not be transferred in any manner other than by will or by the laws of descent
or distribution and may be exercised during the lifetime of the Grantee only by the Grantee; provided, however,
that the Grantee may transfer the Option (a) pursuant to a domestic relations order by a court of competent jurisdiction or (b)
to any Family Member of the Grantee in accordance with Section 17.9.2 of the Plan by delivering to the Company a notice of assignment
in a form acceptable to the Company. No transfer or assignment of the Option to or on behalf of a Family Member under this Section
5 shall be effective until the Company has acknowledged such transfer or assignment in writing.

 

6.
Term of Option. The Option may be exercised only within the term set forth in the Notice of Grant, and may be exercised
during such term only in accordance with the Plan and the terms of the Award Agreement.

 

7.
Withholding.

 

(a)
The Committee shall determine the amount of any withholding or other tax required by law to be withheld or paid by the Company
with respect to any income recognized by the Grantee with respect to the Option.

 

(b)
The Grantee shall be required to meet any applicable tax withholding obligation in accordance with the provisions of Section 17.3
of the Plan.

 

(c)
Subject to any rules prescribed by the Committee, the Grantee shall have the right to elect to meet any withholding requirement
(i) by having withheld from the Option at the appropriate time that number of whole Shares whose Fair Market Value is equal to
the amount of any taxes required to be withheld with respect to the Option, (ii) by direct payment to the Company in cash of the
amount of any taxes required to be withheld with respect to the Option or (iii) by a combination of Shares and cash.

 

8.
Adjustment. Upon any event described in Section 15.1 of the Plan occurring after the Grant Date, the adjustment provisions
as provided for under Section 15.1 of the Plan shall apply to the Option.

 

9.
Bound by Plan and Committee Decisions. By accepting the Option, the Grantee acknowledges that the Grantee has received
a copy of the Plan, has had an opportunity to review the Plan, and agrees to be bound by all of the terms and conditions of the
Plan. In the event of any conflict between the provisions of the Award Agreement and the Plan, the provisions of the Plan shall
control. The authority to manage and control the operation and administration of the Award Agreement and the Plan shall be vested
in the Committee, and the Committee shall have all powers with respect to the Award Agreement as it has with respect to the Plan.
Any interpretation of the Award Agreement or the Plan by the Committee and any decision made by the Committee with respect to
the Award Agreement or the Plan shall be final and binding on all persons.

 

10.
Grantee Representations. The Grantee hereby represents to the Company that the Grantee has read and fully understands the
provisions of the Award Agreement and the Plan and that the Grantee’s decision to participate in the Plan is completely
voluntary. Further, the Grantee acknowledges that the Grantee is relying solely on his or her own advisors with respect to the
tax consequences of the Option.

 

    	Terms and Conditions - Page 2

    	 

    

 

11.
Regulatory Limitations on Exercises. Notwithstanding the other provisions of the Award Agreement, the Committee may impose
such conditions, restrictions and limitations (including suspending the exercise of the Option and the tolling of any applicable
exercise period during such suspension) on the issuance of Common Stock with respect to the Option unless and until the Committee
determines that such issuance complies with (a) any applicable registration requirements under the Securities Act or the Committee
has determined that an exemption therefrom is available, (b) any applicable listing requirement of any stock exchange on which
the Common Stock is listed, (c) any applicable Company policy or administrative rules and (d) any other applicable provision of
state, federal or foreign law, including foreign securities laws where applicable.

 

12.
Market Stand-off Agreement. In connection with a public offering of Shares pursuant to a registration statement (other
than a Form S-8 or successor forms) filed with, and declared effective by, the SEC (a “Public Offering”) and
upon request of the Company or the underwriters managing such Public Offering, the Grantee agrees not to sell, make any short
sale of, loan, grant any option for the purchase of or otherwise dispose of any Shares without the prior written consent of the
Company or such underwriters, as the case may be, for such period of time (not to exceed 180 days) from the effective date of
such registration as may be requested by the Company or such managing underwriters, and to execute an agreement reflecting the
foregoing as may be requested by the underwriters at the time of a Public Offering.

 

13.
Miscellaneous.

 

(a)
Notices. Any notice that either party hereto may be required or permitted to give to the other shall be in writing and
may be delivered personally, by intraoffice mail, by fax, by electronic mail or other electronic means, or via a postal service,
postage prepaid, to such electronic mail or postal address and directed to such person as the Company may notify the Grantee from
time to time; and to the Grantee at the Grantee’s electronic mail or postal address as shown on the records of the Company
from time to time, or at such other electronic mail or postal address as the Grantee, by notice to the Company, may designate
in writing from time to time.

 

(b)
Waiver. The waiver by any party hereto of a breach of any provision of the Award Agreement shall not operate or be construed
as a waiver of any other or subsequent breach.

 

(c)
Entire Agreement. The Award Agreement and the Plan constitute the entire agreement between the parties with respect to
the Option. Any prior agreements, commitments or negotiations concerning the Option are superseded.

 

(d)
Binding Effect; Successors. The obligations and rights of the Company under the Award Agreement shall be binding upon and
inure to the benefit of the Company and any successor corporation or organization resulting from the merger, consolidation, sale,
or other reorganization of the Company, or upon any successor corporation or organization succeeding to substantially all of the
assets and business of the Company. The obligations and rights of the Grantee under the Award Agreement shall be binding upon
and inure to the benefit of the Grantee and the beneficiaries, executors, administrators, heirs and successors of the Grantee.

 

(e)
Governing Law; Consent to Jurisdiction; Consent to Venue. The Award Agreement shall be construed and interpreted in accordance
with the internal laws of the State of New York without regard to principles of conflicts of law thereof, or principles of conflicts
of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction other than the State of New
York. For purposes of resolving any dispute that arises directly or indirectly from the relationship of the parties evidenced
by the Option or the Award Agreement, the parties hereto hereby submit to and consent to the exclusive jurisdiction of the State
of New York and agree that any related litigation shall be conducted solely in the courts of New York County, New York or the
federal courts for the United States for the Southern District of New York, where the Award Agreement is made and/or to be performed,
and no other courts.

 

    	Terms and Conditions - Page 3

    	 

    

 

(f)
Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way
limit or affect the meaning or interpretation of any of the terms or provisions of the Award Agreement.

 

(g)
Amendment. The Award Agreement may be amended at any time by the Committee, provided that no amendment may, without
the consent of the Grantee, materially impair the Grantee’s rights with respect to the Option.

 

(h)
Severability. The invalidity or unenforceability of any provision of the Award Agreement shall not affect the validity
or enforceability of any other provision of the Award Agreement, and each other provision of the Award Agreement shall be severable
and enforceable to the extent permitted by law.

 

(i)
No Rights to Service. Nothing contained in the Award Agreement shall be construed as giving the Grantee any right to be
retained, in any position, as a director, officer, employee, or consultant of the Company or its Affiliates, or shall interfere
with or restrict in any way the rights of the Company or its Affiliates, which are hereby expressly reserved, to remove, terminate
or discharge the Grantee at any time for any reason whatsoever or for no reason, subject to the Company’s articles of incorporation,
bylaws and other similar governing documents and applicable law.

 

(j)
Section 409A. It is intended that the Award Agreement and the Option will be exempt from (or in the alternative will comply
with) Code Section 409A, and the Award Agreement shall be administered accordingly and interpreted and construed on a basis consistent
with such intent. This Section 13(j) shall not be construed as a guarantee of any particular tax effect for the Grantee’s
benefits under the Award Agreement and the Company does not guarantee that any such benefits will satisfy the provisions of Code
Section 409A or any other provision of the Code.

 

(k)
Further Assurances. The Grantee agrees, upon demand of the Company or the Committee, to do all acts and execute, deliver
and perform all additional documents, instruments and agreements that may be reasonably required by the Company or the Committee,
as the case may be, to implement the provisions and purposes of the Award Agreement and the Plan.

 

(l)
Confidentiality. The Grantee agrees that the terms and conditions of the Option award reflected in the Award Agreement
are strictly confidential and, with the exception of the Grantee’s counsel, tax advisor, immediate family, or as required
by applicable law, have not and shall not be disclosed, discussed or revealed to any other persons, entities or organizations,
whether within or outside Company, without prior written approval of Company. The Grantee shall take all reasonable steps necessary
to ensure that confidentiality is maintained by any of the individuals or entities referenced above to whom disclosure is authorized.

 

    	Terms and Conditions - Page 4EX-4.2

 Exhibit 4.2 

SECOND AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

Page 
  

									
	 1.
	 	 Definitions
	  	 	1	 
			
	 2.
	 	 Registration Rights
	  	 	5	 
		 	 2.1
	  	Demand Registration	  	 	5	 
		 	 2.2
	  	Company Registration	  	 	7	 
		 	 2.3
	  	Underwriting Requirements	  	 	7	 
		 	 2.4
	  	Obligations of the Company	  	 	9	 
		 	 2.5
	  	Furnish Information	  	 	10	 
		 	 2.6
	  	Expenses of Registration	  	 	10	 
		 	 2.7
	  	Delay of Registration	  	 	11	 
		 	 2.8
	  	Indemnification	  	 	11	 
		 	 2.9
	  	Reports Under Exchange Act	  	 	13	 
		 	 2.10
	  	Limitations on Subsequent Registration Rights	  	 	14	 
		 	 2.11
	  	“Market Stand-off” Agreement	  	 	14	 
		 	 2.12
	  	Restrictions on Transfer	  	 	15	 
		 	 2.13
	  	Termination of Registration Rights	  	 	16	 
			
	 3.
	 	 Information and Inspection Rights
	  	 	16	 
		 	 3.2
	  	Inspection	  	 	17	 
		 	 3.3
	  	Termination of Information	  	 	18	 
		 	 3.4
	  	Confidentiality	  	 	18	 
			
	 4.
	 	 Rights to Future Stock Issuances
	  	 	19	 
		 	 4.1
	  	Right of First Offer	  	 	19	 
		 	 4.2
	  	Termination	  	 	20	 
			
	 5.
	 	 Additional Covenants
	  	 	21	 
		 	 5.1
	  	Insurance	  	 	21	 
		 	 5.2
	  	Employee Agreements	  	 	21	 
		 	 5.3
	  	Employee Stock	  	 	21	 
		 	 5.4
	  	Board Matters	  	 	21	 
		 	 5.5
	  	Successor Indemnification	  	 	22	 
		 	 5.6
	  	Expenses of Counsel	  	 	22	 
		 	 5.7
	  	Indemnification Matters	  	 	22	 
		 	 5.8
	  	Termination of Covenants	  	 	23	 
		 	 5.9
	  	Right to Conduct Activities	  	 	23	 
		 	 5.10
	  	Matters Requiring Preferred Director Approval	  	 	23	 
			
	 6.
	 	 Miscellaneous
	  	 	24	 
		 	 6.1
	  	Successors and Assigns	  	 	24	 
		 	 6.2
	  	Governing Law	  	 	25	 
		 	 6.3
	  	Counterparts	  	 	25	 
		 	 6.4
	  	Titles and Subtitles	  	 	25	 

							
		  	6.5	  	Notices	  	25
		  	6.6	  	Amendments and Waivers	  	26
		  	6.7	  	Severability	  	27
		  	6.8	  	Aggregation of Stock	  	27
		  	6.9	  	Additional Investors	  	27
		  	6.10	  	Entire Agreement	  	27
		  	6.11	  	Dispute Resolution	  	27
		  	6.12	  	Delays or Omissions	  	28

 Schedule A - Schedule of Investors 
  

  
 2 

 SECOND AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of January,
2018, by and among AVROBIO, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (together with any subsequent investors, or transferees, who become parties hereto as
“Investors” in accordance with Subsection 6.1 or Subsection 6.9 below, the “Investors”). 
 RECITALS

 WHEREAS, the Company and certain of the Investors (the “Prior Investors”) have previously entered into
that certain Amended and Restated Investors’ Rights Agreement dated as of July 21, 2016 (the “Prior Agreement”); 

WHEREAS, the Company and the Investors are parties to the Series B Preferred Stock Purchase Agreement of even date herewith (the
“Purchase Agreement”); 
 WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior
Agreement and to accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement; 
 WHEREAS,
the Company and the Prior Investors who have signed this Agreement constitute the requisite parties to amend and restate the Prior Agreement; and 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Investors to invest funds in the Company
pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall amend and restate the Prior Agreement and govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to
the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement; 

NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, limited partner, member, employee, officer or director of such Person or any venture capital fund now or
hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. For purposes of this definition, the term “control” when used with respect to any Person
means the power to direct the management or policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise, and the terms “controlling” and “controlled” shall have
meanings correlative to the foregoing. 

 1.2 “Aisling” means Aisling Capital IV, L.P. 

1.3 “Atlas” means Atlas Venture Fund X, L.P. 

1.4 “Brace” means Brace Pharmaceuticals LLC. 

1.5 “Clarus” means Clarus Lifesciences III, LLP. 

1.6 “Common Stock” means shares of the Company’s common stock, par value $0.0001 per share. 

1.7 “Competitor” means a Person engaged, directly or indirectly (including through any partnership,
limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the research, development or commercialization of human biopharmaceutical products involving lentiviral-based gene therapy
for rare disease or neoplastic cells transduced to express molecules to treat cancer, but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than twenty percent (20)% of
the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the Board of Directors of any Competitor. Notwithstanding anything herein, the Company acknowledges that none of Surveyor,
Atlas, SV or Clarus shall be deemed to be a Competitor solely by virtue of its (or any of its Affiliates’) status as a venture capital investor or equity holdings in a Competitor. 

1.8 “Cormorant” means, collectively, Cormorant Private Healthcare Fund I, LP, Cormorant Global Healthcare
Master Fund, LP, and CRMA SPV, L.P. 
 1.9 “Damages” means any loss, damage, claim or liability (joint or
several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon:
(i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto;
(ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any
of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.10 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable
for (in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.11 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

  
 2 

 1.12 “Excluded Registration” means (i) a registration
relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that
does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered. 
 1.13 “Eventide”
means Eventide Healthcare & Life Sciences Fund. 
 1.14 “FOIA Party” means a Person that, in the
reasonable determination of the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5
U.S.C. 552 (“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

1.15 “Form S-1” means such form under the Securities Act as in
effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.16 “Form S-3” means such form under the Securities Act as in
effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.17 “GAAP” means generally accepted accounting principles in the United States. 

1.18 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.19 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.20 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 1.21 “IPO” means the Company’s first underwritten public offering of its Common Stock
under the Securities Act. 
 1.22 “Key Employee” means any executive-level employee (including, division
director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

  
 3 

 1.23 “Leerink” means, collectively, Leerink Holdings LLC, and
Leerink Swann Co-Investment Fund, LLC. 
 1.24 “Major Investor” means any Investor that, individually or
together with such Investor’s Affiliates, holds at least 750,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.25 “Morningside” means Morningside Venture Investments Limited. 

1.26 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.27 “Person” means any individual, corporation, partnership, trust, limited liability company, association or
other entity. 
 1.28 “Preferred Directors” means directors of the Company that the holders of record
of the Preferred Stock are entitled to elect pursuant to the Company’s Certificate of Incorporation. 
 1.29
“Preferred Majority” shall mean the Requisite Preferred Holders (as defined in the Company’s Certificate of Incorporation); provided, however that subsequent to the consummation of the IPO, Preferred Majority shall mean the
holders of a majority of the shares of Registrable Shares issued upon conversion of the Series Seed Preferred Stock, Series A Preferred Stock and the Series B Preferred Stock. 

1.30 “Preferred Stock” means, collectively, the Series B Preferred Stock, Series A Preferred Stock and the
Series Seed Preferred Stock. 
 1.31 “Registrable Securities” means (i) the Common Stock issuable or
issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of
the Company, acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution
with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights
under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.32 “Registrable Securities then outstanding” means the number of shares determined by adding the number of
shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

  
 4 

 1.33 “Restricted Securities” means the securities of the Company
required to be notated with the legend set forth in Subsection 2.12(b) hereof. 
 1.34 “SEC”
means the Securities and Exchange Commission. 
 1.35 “SEC Rule 144” means Rule 144 promulgated by the SEC
under the Securities Act. 
 1.36 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities
Act. 
 1.37 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 1.38 “Selling Expenses” means all underwriting discounts, selling commissions,
and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in
Subsection 2.6. 
 1.39 “Series A Preferred Stock” means shares of the Company’s Series A
Preferred Stock, par value $0.0001 per share. 
 1.40 “Series B Preferred Stock” means shares of the
Company’s Series B Preferred Stock, par value $0.0001 per share. 
 1.41 “Series Seed Preferred Stock”
means shares of the Company’s Series Seed Preferred Stock, par value $0.0001 per share. 
 1.42 “Surveyor” means
Citadel Multi-Strategy Equities Master Fund Ltd. 
 1.43 “SV” means SV Life Sciences Fund VI, L.P and SV
Life Sciences Fund VI Strategic Partners, L.P. 
 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date
of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from the Preferred Majority that the Company file a Form S-1 registration statement with respect to at least fifty percent (50%) of the Registrable Securities then outstanding having an anticipated aggregate offering price, net of Selling Expenses, of not less than
$10 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as
practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all
Registrable Securities 

  
 5 

 
that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form
S-3 registration statement, the Company receives a request from Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company
shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the
date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any
other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection
2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such registration
statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate
reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company
unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be
tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve
(12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection
2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a
Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations
pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made
pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b)(i) during the period 

  
 6 

 
that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a
Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations
pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d)
until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right
to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give
each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all
of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective
date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with
Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the
Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if
the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that
otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such 

  
 7 

 
other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such
underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of
shares allocated to any Holder to the nearest one hundred (100) shares. 
 (b) In connection with any offering involving an
underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of
the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of
securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is
compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion
determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included
in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such
selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the
foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or
(ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be
excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any
selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners,
retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder”
shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the
underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included. 

  
 8 

 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to sixty (60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 

  
 9 

 (h) promptly make available for inspection by the selling Holders, any managing underwriter(s)
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate
documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in
each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification
fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $40,000, of one counsel for the selling Holders (“Selling Holder Counsel”),
shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is
subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be
included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be;
provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request
and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections
2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities
registered on their behalf. 

  
 10 

 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction
restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company
be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or
other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each selling
Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the
Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of
any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by
way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by
such Holder. 

  
 11 

 (c) Promptly after receipt by an indemnified party under this Subsection 2.8 of
notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly
with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified
parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying
party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the
indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case
(x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such 

  
 12 

 
fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or
payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution in the underwriting agreement
approved by the Preferred Majority entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file with
the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
S-3 (at any time after the Company so qualifies to use such form). 

  
 13 

 2.10 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Preferred Majority, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would provide to such holder the right to
include securities in any registration on other than on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include; or (ii) allow
such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this
Agreement in accordance with Subsection 6.9. 
 2.11 “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the effective date of the
registration statement relating to the IPO and ending on the date specified by the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other period as may be requested by the Company or an underwriter to
accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE
Rule 472(f)(4), or any successor provisions or amendments thereto; provided, however, that in no event will the restricted period extend beyond two hundred sixteen (216) days after the effective date of such registration statement) or such
longer period approved by the Preferred Majority; (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration
statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in
clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall not apply to the sale of any shares to an underwriter
pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors and stockholders individually (and with their Affiliates)
owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same or substantially similar restrictions. The underwriters
in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a
party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further
effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to
such agreements. 

  
 14 

 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the
Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall
give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed

  
 15 

 
sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell,
pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance
with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this
Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive
legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in
order to establish compliance with any provisions of the Securities Act. 
 2.13 Termination of Registration Rights. The right of any
Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s
shares without limitation during a three-month period without registration; and 
 (c) the fifth anniversary of the IPO. 

3. Information and Inspection Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors
(including a majority of the Preferred Directors) has not reasonably determined that such Major Investor is a Competitor: 
 (a) as soon as
practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and
(iii) a statement of stockholders’ equity as of the end of such year, with each being prepared in accordance with GAAP, audited and certified by independent public accountants selected by the Board of Directors (including a majority of the
Preferred Directors); 
 (b) as soon as practicable, but in any event within thirty (30) days after the end of each of the first three
(3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such
financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

  
 16 

 (c) as soon as practicable, but in any event within thirty (30) days after the end of each
of the first three (3) quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the
end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock
options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial
officer or chief executive officer of the Company as being true, complete, and correct; 
 (d) as soon as practicable, but in any event
thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance
sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 

(e) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor
may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade
secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company, it being agreed that the confidentiality provisions of Section 3.4 hereof shall constitute such an
enforceable confidentiality agreement with respect to any Major Investor party to this Agreement); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of submission or filing of a registration statement if it reasonably concludes it must do so to comply with
the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its
commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit
each Major Investor (provided that the Board of Directors (including a majority of the Preferred Directors) has not reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s expense, to
visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during 

  
 17 

 
normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection
3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company,
it being agreed that the confidentiality provisions of Section 3.5 hereof shall constitute such an enforceable confidentiality agreement with respect to any Major Investor party to this Agreement) or the disclosure of which would adversely
affect the attorney-client privilege between the Company and its counsel. 
 3.3 Termination of Information. The covenants set forth
in Subsection 3.1 and Subsection 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) when the Company first becomes subject to the periodic reporting
requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation. 

3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor
without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company;
provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary or reasonably appropriate to obtain their services in
connection with monitoring its investment in the Company or interpreting, enforcing, or defending a claim under an agreement to which such Investor and the Company are both party; (ii) to any prospective purchaser of any Registrable Securities
from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.4; (iii) to any existing or prospective Affiliate, limited partner, partner, member, stockholder, or wholly owned subsidiary of
such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information and such Person is bound by
confidentiality obligations with respect to any confidential information of the Company to the same degree as such Investor hereunder; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company
of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. This Subsection 3.4 shall supersede any confidentiality agreement executed by Aisling, Atlas, Brace, Clarus, Cormorant, Eventide, Leerink,
Morningside, Surveyor or SV or any of their respective Affiliates and the Company. The Company acknowledges that each of Aisling, Atlas, Brace, Clarus, Cormorant, Eventide, Leerink, Morningside, Surveyor and SV and their respective representatives
and Affiliates (the “Investor Parties”) are or may be in the business of venture capital investing and, therefore, review business plans and other materials containing proprietary information of many enterprises, including enterprises
which may have products or services which compete directly or indirectly with those of the Company and that have and may provide to the Investor Parties, 

  
 18 

 
ideas, plans or other information which is similar to that embodied in the confidential information of the Company and nothing in this Agreement shall preclude or in any way restrict the Investor
Parties from investing in any particular enterprise (including but not limited to participating fully as a member of the board of directors in such enterprise) whether or not such enterprise has products or services which compete with those of the
Company. The Company acknowledges that some knowledge may be gained by the Investor Parties from reviewing the confidential information of the Company that cannot be separated from any of the Investors Parties’ overall knowledge and, provided
that the Investor Parties do not disclose any confidential information of the Company to a third party in violation of this Agreement, including any companies in which any of the Investor Parties invests, such general industry knowledge shall be
permitted to be used in the ordinary course of business of each of the Investor Parties. 
 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it
deems appropriate, among (i) itself (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Investor (“Investor Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner (x) is not a Competitor
or FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, and (y) agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement (provided that any Competitor or FOIA
Party to whom the foregoing right of first offer is apportioned shall not be entitled to any rights as a Major Investor or Investor, as applicable, under Subsections 3.1, 3.2 and 4.1 hereof but the Investor that so apportioned
the right of first offer shall retain all rights hereunder to which it would otherwise be entitled in accordance with the terms hereof). 

(a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to
offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Preferred Stock on an as converted to Common Stock basis then held by such Major Investor
bears to the total Preferred Stock on an as converted to Common Stock basis held by all Major Investors. At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire
all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has

  
 19 

 
given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of
the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Preferred Stock on an as-converted to Common Stock basis issued and held, then
held, by such Fully Exercising Investor bears to the Preferred Stock on an as-converted to Common Stock basis issued and held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares.
The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c).

 (c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection
4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a
price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not
consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this
Subsection 4.1. 
 (d) The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities
(as defined in the Company’s Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series B Preferred Stock pursuant to the Purchase Agreement. 

(e) Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this Subsection 4.1, the Company may
elect to give notice to the Major Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each Major Investor shall have twenty (20) days from the
date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s percentage-ownership position, calculated as set forth in Subsection 4.1(b) before
giving effect to the issuance of such New Securities. The closing of such sale shall occur within sixty (60) days of the date notice is given to the Major Investors. 

4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect
(i) immediately before the consummation of a Qualified IPO, as such term is defined in the Company’s Certificate of Incorporation, or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of
Incorporation, whichever event occurs first. 

  
 20 

 5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to maintain Directors and Officers liability insurance from
financially sound and reputable insurers in an amount and on terms and conditions satisfactory to the Board of Directors, including a majority of the Preferred Directors, and will use commercially reasonable efforts to cause such insurance policies
to be maintained until such time as the Board of Directors, including a majority of the Preferred Directors, determines that such insurance should be discontinued. The policy shall not be cancelable by the Company without prior approval by the Board
of Directors including a majority of the Preferred Directors. Notwithstanding any other provision of this Section 5.1 to the contrary, for so long as any Preferred Director is serving on the Board of Directors, the Company
shall not cease to maintain a Directors and Officers liability insurance policy in an amount of at least two million dollars ($2.0 million) unless approved by such Preferred Director, and the Company shall annually, within one hundred twenty
(120) days after the end of each fiscal year of the Company, deliver to each Preferred Director a certification that such a Directors and Officers liability insurance policy remains in effect. 

5.2 Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged
by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) each Key Employee to enter
into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors (including a majority of the Preferred Directors), after the date hereof, or, otherwise, substantially in the form
provided to counsel for the Investors before the date hereof as the Company’s standard form agreement. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced
agreements or any restricted stock agreement between the Company and any employee, without the consent of a majority of the Preferred Directors. 

5.3 Employee Stock. Unless otherwise approved by the Board of Directors, including a majority of the Preferred Directors, any
employees or consultants of the Company who purchases, receives options to purchase, or receives awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as
applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares
vesting in equal monthly installments over the following thirty-six (36) months or in equal quarterly installments over the following twelve (12) quarters, (ii) a market stand-off provision substantially similar to that in Subsection 2.11 and (iii) provisions requiring such employee or consultant to enter into each of the Voting Agreement pursuant to Section 7.1(b)
thereof and Right of First Refusal and Co-Sale Agreement pursuant to Section 6.17 thereof, in each case as applicable to such employee or consultant. In addition, unless otherwise approved by the Board of
Directors, including a majority of the Preferred Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon
termination of employment of a holder of restricted stock. 
 5.4 Board Matters. Unless otherwise determined the Board of Directors,
including a majority of the Preferred Directors, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable
out-of-pocket travel (consistent with the Company’s 

  
 21 

 
travel policy) and other expenses incurred in connection with the performance of their duties as directors and attending meetings of the Board of Directors and committees thereof and attending
events on behalf of the Company. Each of the Preferred Directors shall have the right to sit on any audit committee or compensation committee of the Board of Directors or any other committee with authority to act on behalf of the Company without
specific approval from the Board of Directors. As of the date hereof, Bruce Booth shall be the Chairman of the Board of Directors. 
 5.5
Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent
necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such
transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 

5.6 Expenses of Counsel. In the event of a transaction which is a Sale of the Company (as defined in the Voting Agreement), the
reasonable fees and disbursements, not to exceed $25,000, of one counsel for the Investors (“Investor Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction
which, if consummated would constitute a Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including, without limitation, the
initial and all subsequent drafts of memoranda of understanding, letters of intent and other transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the
transactions which, individually or when aggregated with others would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company’s counsel and investment bankers to share) such materials when distributed
to the Company’s executives and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement
to enhance the ability of the parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such
an agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or
joint defense agreement in order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel
and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. 
 5.7
Indemnification Matters. The Company hereby acknowledges that one (1) or more of the Preferred Directors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or
insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company 

  
 22 

 
hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses
or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full
amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company
(or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any
and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund
Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement
or payment to all of the rights of recovery of such Fund Director against the Company. 
 5.8 Termination of Covenants. The
covenants set forth in this Section 5, except for Subsections 5.5, 5.6, 5.7, 5.8 and 5.9, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when
the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation,
whichever event occurs first. 
 5.9 Right to Conduct Activities. The Company hereby agrees and acknowledges that each
of Aisling, Atlas, Brace, Clarus, Cormorant, Eventide, Leerink, Morningside, Surveyor and SV (each a “Fund”) is a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed
competitive with the Company’s business (as currently conducted or as currently proposed to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, no Fund shall be liable to the Company for any claim
arising out of, or based upon, (i) the investment by such Fund or its Affiliates in any entity competitive with the Company, or (ii) actions taken by any Affiliate, partner, officer or other representative of such Fund to assist any
such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the
foregoing shall not relieve (x) any of the Funds from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company
from any liability associated with his or her fiduciary duties to the Company. 
 5.10 Matters Requiring Preferred Director
Approval. So long as there are any Preferred Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the affirmative vote a majority
of the Preferred Directors: 
 (a) make any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership, unless it is wholly owned by the Company; 

  
 23 

 (b) make any loan or advance to any person, including, any employee or director, except advances
and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(c) guarantee any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 

(d) make any investment inconsistent with any investment policy approved by the Board of Directors; 

(e) incur any aggregate indebtedness in excess of $100,000 that is not already included in a Board-approved budget, other than trade credit
incurred in the ordinary course of business; 
 (f) enter into or be a party to any transaction with any director, officer or employee of
the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person, including without limitation any “management bonus” or similar plan
providing payments to employees in connection with a Deemed Liquidation Event, as such term is defined in the Restated Charter, except for transactions contemplated by this Agreement and the Purchase Agreement; 

(g) hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards; 

(h) change the principal business of the Company, enter new lines of business, or exit the current line of business; 

(i) sell, assign, license, pledge or encumber material technology or intellectual property, other than licenses granted in the ordinary course
of business; 
 (j) enter into any corporate strategic relationship involving the payment contribution or assignment by the Company or to
the Company of assets greater than $100,000; or 
 (k) permit AvroBio, Inc. (a corporation formed under the laws of Ontario and a
wholly-owned subsidiary of the Company, or the “Canadian Subsidiary”) to have any assets, liabilities or operations, unless, at such time and continuing for so long as the Canadian Subsidiary has any assets, liabilities or operations, the
board of directors or other governing body of the Canadian Subsidiary shall be composed of the same members as the Board of Directors of the Company at such time (subject to applicable law), and the other covenants set forth in this
Section 5.10 shall be applicable to the Canadian Subsidiary to the same extent as they are to the Company. 
 6. Miscellaneous.

 6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a
Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust 

  
 24 

 
for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 1,500,000 shares of Registrable Securities
(subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of
the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the
terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an
Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with
those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single
attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure
to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of
Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. 

6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.
All 

  
 25 

 
communications shall be sent to the respective parties at their addresses as set forth on Schedule A or to the principal office of the Company and to the attention of the Chief Executive Officer,
in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy (which shall not constitute
notice) shall also be sent to Arthur R. McGivern, Esq., Goodwin Procter LLP, to the following address: 100 Northern Avenue, Boston, MA 02210 and if notice is given to Investors, a copy shall also be given to Brian Lenihan, Choate, Hall &
Stewart LLP, Two International Place, Boston, MA 02110 (which shall not constitute notice)and Suzanne P. Hamel and Thomas B. Rosedale, BRL Law Group LLC, 425 Boylston Street, Third Floor, Boston, MA 02116 (which shall not constitute notice). 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Preferred Majority; provided, that, that the Company may in its sole discretion waive
compliance with Subsection 6.1 (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 6.1 shall be deemed to be a waiver); and
provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party; and provided further that the terms of Section 1.20, the first paragraph of this
Section 6.6 and the first sentence of the second paragraph of this Section 6.6 may be amended, modified or terminated and the observance of any term of such sections may be waived only with the written consent of the Company and the
holders of at least a majority of outstanding Series B Preferred Stock party to this Agreement. 
 Notwithstanding the foregoing, this
Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without (i) the written consent of such Investor, unless such amendment, termination, or waiver applies to all
Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by
its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction); provided, however, that if, after giving effect to such waiver of Section 4 with respect to a
particular transaction, an Investor purchases securities in such transaction or issuance (such Investor, a “Participating Investor”), such waiver of the provisions of Section 4 shall be deemed to apply to each Major Investor
only if the Major Investors have been provided the opportunity to purchase a proportional number of the securities in such transaction based on the pro rata purchase right of each Major Investor set forth in Section 4, assuming a transaction
size determined based upon the amount purchased by the Participating Investor that invested the largest percentage in such transaction, or (ii) the written consent of holders of at least a majority of the outstanding Series B Preferred Stock,
if such amendment, termination or waiver adversely affects the rights of holders of the Series B Preferred Stock in a different and disproportionate manner than the holders of the Series A Preferred Stock or the Series Seed Preferred Stock. The
Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance
with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances,
shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

  
 26 

 6.7 Severability. In case any one or more of the provisions contained in this Agreement
is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be
reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of
Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as
among themselves in any manner they deem appropriate. 
 6.9 Additional Investors. Notwithstanding anything to the contrary contained
herein, if the Company issues additional shares of the Company’s Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Preferred Stock may become a party to this
Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such
joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled, including without limitation, the Prior
Agreement. 
 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the
state courts of the Commonwealth of Massachusetts and to the jurisdiction of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement,
(b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the Commonwealth of Massachusetts or the United States District Court for the District of
Massachusetts, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that
its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof
may not be enforced in or by such court. 

  
 27 

 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION
BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL
DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY
CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL
COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12
Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of
such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be
deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

[Remainder of Page Intentionally Left Blank] 

  
 28 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	AVROBIO, INC.
		
	By:	 	 /s/ Geoffrey MacKay

	Name:	 	Geoffrey MacKay
	Title:	 	President and Chief Executive Officer

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD.
	
	By: Citadel Advisors LLC, its portfolio manager
	
	 /s/ Noah Goldberg

	Name: Noah Goldberg
	Title: Authorized Signatory

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Cormorant Private Healthcare Fund I, LP
		
	By:	 	Cormorant Private Healthcare GP, LLC
	By:	 	Bihua Chen, Managing Member of the GP
		
	By:	 	 /s/ Bihua Chen

	Name:	 	 Bihua Chen

	Title:	 	  

	
	Cormorant Global Healthcare Master Fund, LP
		
	By:	 	Cormorant Private Healthcare GP, LLC
	By:	 	Bihua Chen, Managing Member of the GP
		
	By:	 	 /s/ Bihua Chen

	Name:	 	 Bihua Chen

	Title:	 	  

	
	CRMA SPV, L.P.
		
	By:	 	Cormorant Asset Management, LLC
	By:	 	Bihua Chen, CEO/CIO
		
	By:	 	 /s/ Bihua Chen

	Name:	 	 Bihua Chen

	Title:	 	  

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	AISLING CAPITAL IV, L.P.
		
	By:	 	 /s/ Robert Wenzel

	Name:	 	Robert Wenzel
	Title:	 	Chief Financial Officer

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	LEERINK HOLDINGS LLC
		
	By:	 	 /s/ Jim Boylan

	Name:	 	Jim Boylan
	Title:	 	President
	
	LEERINK SWANN CO-INVESTMENT FUND, LLC
		
	By:	 	 /s/ Jim Boylan

	Name:	 	Jim Boylan
	Title:	 	Manager

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BRACE PHARMACEUTICALS LLC
		
	By:	 	 /s/ Vinzenz Ploerer

	Name:	 	Vinzenz Ploerer
	Title:	 	President & Chief Executive Officer

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	MUTUAL FUND SERIES TRUST, ON BEHALF OF EVENTIDE HEALTHCARE & LIFE SCIENCES FUND
		
	By:	 	 /s/ Erik Naviloff

	Name:	 	Erik Naviloff
	Title:	 	Treasurer

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BIOMARIN PHARMACEUTICAL INC.

 
			
		
	By:	 	 /s/ Brinda Balakrishnan

	Name:	 	Brinda Balakrishnan
	Title:	 	Group Vice President

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 ALEXANDRIA VENTURE INVESTMENTS, LLC,

a Delaware limited liability company

	
	By: Alexandria Real Estate Equities, Inc., a Maryland corporation, its managing member

 
			
		
	By:	 	 /s/ Aaron Jacobson

	Name:	 	 Aaron Jacobson

	Title:	 	 VP - Corporate Counsel

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 For and on behalf of

Morningside Venture Investments Limited

		
	By:	 	 /s/ Hon Kit Bing        /s/ Jill Marie Franklin

	Name:	 	Hon Kit Bing/Jill Marie Franklin
	Title:	 	Authorized Signatories

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ATLAS VENTURE FUND X, L.P.
	
	By: Atlas Venture Associates X, L.P. Its General Partner
	
	By: Atlas Venture Associates X, LLC Its General Partner
		
	By:	 	 /s/ Ommer Chohan

	Name:	 	Ommer Chohan
	Title:	 	Chief Financial Officer

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SV Life Sciences Fund VI, L.P.
		
	By:	 	SV Life Sciences Fund VI (GP), L.P., its sole General Partner
		
	By:	 	SVLSF VI, LLC, its sole general partner
		
	By:	 	 /s/ Denise W. Marks

	Name:	 	 Denise W. Marks

	Title:	 	 SVLSF VI, LLC, Member

	
	SV Life Sciences Fund VI Strategic Partners, L.P.
		
	By:	 	SV Life Sciences Fund VI (GP), L.P., its sole General Partner
		
	By:	 	SVLSF VI, LLC, its sole general partner
		
	By:	 	 /s/ Denise W. Marks

	Name:	 	 Denise W. Marks

	Title:	 	 SVLSF VI, LLC, Member

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	CLARUS LIFESCIENCES III, L.P.
	
	BY ITS GENERAL PARTNER, CLARUS VENTURES III GP, LP
	BY ITS GENERAL PARTNER, CLARUS VENTURES III, LLC
	
	BY: /s/ Scott
Requadt                                        
        
	SCOTT REQUADT
	MANAGING DIRECTOR 

 SIGNATURE PAGE TO 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 SCHEDULE A 

Investors 
  

					
	 Name and Address
	  	Number of Shares Held	 
	 Citadel Multi-Strategy Equities Master Fund Ltd.

c/o Citadel Advisors LLC

601 Lexington Avenue, New York, New York

Attention: Noah Goldberg, Senior Deputy General Counsel

CitadelAgreementNotice@citadel.com
	  	 	5,610,360	 
		
	 Cormorant Private Healthcare Fund I, LP

200 Clarendon Street, 52nd Floor

Boston, MA 02116

Attention: Jake Abdolmohammadi
	  	 	4,366,543	 
		
	 Cormorant Global Healthcare Master Fund, LP

200 Clarendon Street, 52nd Floor

Boston, MA 02116

Attention: Jake Abdolmohammadi
	  	 	1,005,938	 
		
	 CRMA SPV, L.P.

PO Box 309

Ugland House

Grand Cayman

KY1-1104 Cayman Islands

Copy to:

200 Clarendon Street, 52nd Floor

Boston, MA 02116

Attention: Jake Abdolmohammadi
	  	 	237,879	 
		
	 Aisling Capital IV, L.P.

888 Seventh Avenue, 12th Floor

New York, NY 10106

Attn: Drew Schiff and

Attn: Chief Financial Officer

Fax: 212 651 6379, with copy to:

McDermott Will & Emery LLP

340 Madison Avenue

New York, NY 10173-1922

Attn: Todd Finger

Fax: 212 547 5444
	  	 	2,805,179	 
		
	 Mutual Fund Series Trust, on behalf of Eventide Healthcare & Life Sciences Fund

c/o Finny Kuruvilla, One International Place,

Suite 3510, Boston, MA 02110
	  	 	2,805,179	 
		
	 Brace Pharmaceuticals LLC

155 Gibbs Street, Suite 406, Rockville, MD, 20850
	  	 	1,402,589	 
		
	 Morningside Venture Investments Limited

Attn: Louise Garbarino

2nd Floor, Le Prince de Galles

3-5 Avenue des Citronniers

MC 98000, Monaco

T: 011-377-97-97-47-37

F: 011-377-97-97-47-30

lgarbarino@thc-mgt.mc with copies to:

1)McCarthy Legal Services

Attn: Stephanie O’Brien, Esq.

1188 Centre Street
	  	 	935,059	 

					
	 Newton Centre, MA 02459

T: (617) 244-2800

F: (617) 244-2889

obrien@morningsidenewton.com, and
  

2) Springfield Financial Advisory Limited

Attn: Alice Li/Makim Ma

22nd Floor Hang Lung Centre

2-20 Paterson Street

Causeway Bay, Hong Kong

T: 011-852-2576-6800

F: 011-852-2881-5741

alice.li@springfld.com

MakimMa@springfld.com
	  			
		
	 Leerink Holdings LLC

c/o Leerink Partners LLC

One Federal Street, 37th Floor

Boston, MA 02110

Attention: General Counsel
	  	 	233,764	 
		
	 Leerink Swann Co-Investment Fund, LLC

c/o Leerink Partners LLC

One Federal Street, 37th Floor

Boston, MA 02110

Attention:     General Counsel
	  	 	233,765	 
		
	 Atlas Venture Fund X, L.P.

400 Technology Square, 10th Floor

Cambridge, MA 02139

Attention:    General Counsel, E-mail:    bruce@atlasventure.com, with a
copy to ommer@atlasventure.com
	  	 	3,740,239	 
		
	 SV Life Sciences Fund VI, L.P.

One Boston Place

201 Washington Street, Suite 3900

Boston, Massachusetts 02108

Attention: Josh Resnick and Denise Marks

E-mail:

jresnick@svhealthinvestors.com

dmarks@svhealthinvestors.com
	  	 	1,808,211	 
		
	 SV Life Sciences Fund VI Strategic

Partners, L.P.

One Boston Place

201 Washington Street, Suite 3900

Boston, Massachusetts 02108

Attention: Josh Resnick and Denise Marks

E-mail:

jresnick@svhealthinvestors.com

dmarks@svhealthinvestors.com
	  	 	61,908	 
		
	 Clarus Lifesciences III, LLP

101 Main Street, Suite 1210

Cambridge MA 02142

Attention: Scott Requadt and Rob Liptak

E-mail:

srequadt@clarusfunds.com   rliptak@clarusfunds.com
	  	 	2,805,179	 

					
	 Alexandria Venture Investments, LLC

385 E. Colorado Blvd., Suite 299, Pasadena, CA 91101

Attention: Aaron Jacobson
	  	 	233,765	 
		
	 BioMarin Pharmaceutical Inc.

105 Digital Drive, Novato, CA 94949

Attention: General Counsel
	  	 	233,765	 
		
	 TOTAL:
	  	 	28,519,322

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]